BBP vs IBBQ

BBPAVirtus Biotech ETF

IBBQAInvesco Nasdaq Biotechnology ETF

In short

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

Stated mandate

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

Why people hold it

• BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
• 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
• Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
• One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

• IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
• Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
• Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
• Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

Worth knowing

• BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
• Income is not the point here. The fund has not been paying distributions, so the return story is price.
• An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

• IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
• One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
• Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

Full BBP profile⁠

Full IBBQ profile⁠